CSL Gross Profit
Delisted·Jun 19, 2026
The Gross Profit of CSL (CSL.AX) as of Jul 25, 2026 is 8.08 B USD. In the previous year, Gross Profit was 7.67 B USD — a change of 5.32% (higher).
Get this data via API
Financial Data API
Gross Profit
8.08 BUSD
YoY
5.32%
Last updated:
Gross Profit of CSL is 2026 8.08 B USD. Gross Profit of CSL was 2025 7.67 B USD. It decreases by 5.32% higher compared to the previous year.
The CSL Gross Profit history
3 Years
10 Years
25 Years
Max
GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2024
51.83 base
Jan 1, 2025
51.93 base
Jan 1, 2026 (e)
50.48 base
Jan 1, 2027 (e)
48.48 base
Jan 1, 2028 (e)
46.28 base
Jan 1, 2029 (e)
42.25 base
Jan 1, 2030 (e)
38.74 base
Jan 1, 2031 (e)
36.68 base
| YEAR | GROSS MARGIN (%) |
|---|---|
| 2031 est | 36.68 |
| 2030 est | 38.74 |
| 2029 est | 42.25 |
| 2028 est | 46.28 |
| 2027 est | 48.48 |
| 2026 est | 50.48 |
| 2025 | 51.93 |
| 2024 | 51.83 |
| 2023 | 51.28 |
| 2022 | 54.27 |
| 2021 | 56.68 |
| 2020 | 57.11 |
| 2019 | 55.95 |
| 2018 | 55.38 |
| 2017 | 51.94 |
| 2016 | 50.08 |
| 2015 | 53.70 |
| 2014 | 52.86 |
| 2013 | 53.38 |
| 2012 | 50.39 |
| 2011 | 50.74 |
| 2010 | 52.59 |
| 2009 | 52.21 |
| 2008 | 49.17 |
| 2007 | 47.56 |
| 2006 | 41.39 |
Access this data via the Eulerpool API
CSL Revenue
CSL Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
14.80 B USD
3.81 B USD
2.64 B USD
Jan 1, 2025
15.56 B USD
4.10 B USD
3.00 B USD
Jan 1, 2026 (e)
16.00 B USD
4.86 B USD
3.40 B USD
Jan 1, 2027 (e)
16.66 B USD
5.12 B USD
3.67 B USD
Jan 1, 2028 (e)
17.46 B USD
5.44 B USD
3.96 B USD
Jan 1, 2029 (e)
19.12 B USD
5.70 B USD
4.41 B USD
Jan 1, 2030 (e)
20.85 B USD
5.94 B USD
4.75 B USD
Jan 1, 2031 (e)
22.03 B USD
0.00 USD
5.07 B USD
CSL Margins
CSL stock margins
The CSL margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CSL. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CSL.
3 Years
5 Years
10 Years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
51.83 %
25.76 %
17.85 %
Jan 1, 2025
51.93 %
26.38 %
19.30 %
Jan 1, 2026 (e)
51.93 %
30.39 %
21.27 %
Jan 1, 2027 (e)
51.93 %
30.71 %
22.05 %
Jan 1, 2028 (e)
51.93 %
31.16 %
22.69 %
Jan 1, 2029 (e)
51.93 %
29.82 %
23.09 %
Jan 1, 2030 (e)
51.93 %
28.50 %
22.80 %
Jan 1, 2031 (e)
51.93 %
0.00 %
23.01 %
CSL Stock analysis
What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country.
CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd.
CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health.
CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products.
In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis.
In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle.
CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field.
The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia.
CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019.
CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.
Frequently Asked Questions about CSL stock
Gross Profit of CSL is 8.08 B USD in 2026.
Access this data via the Eulerpool API
Income Statement — CSL
All Key Metrics — CSL
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth